Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03KIA
|
|||
| Former ID |
DNC000403
|
|||
| Drug Name |
Cerivastatin
|
|||
| Synonyms |
cerivastatin; Baycol; cerivastatin acid; Lipobay; 145599-86-6; Cerivastatin [INN:BAN]; UNII-AM91H2KS67; CHEBI:3558; AM91H2KS67; HSDB 7357; (3R,5S,6E)-7-(4-(p-Fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)-3-pyridyl)-3,5-dihydroxy-6-heptenoic acid; (3R,5S,6E)-7-(4-(4-Fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-6-heptenoic acid; 143201-11-0; 6-Heptenoic acid, 7-(4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-, (3R,5S,6E)-; Statins
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hyperlipidaemia [ICD-11: 5C80; ICD-10: E78.5] | Approved | [1], [2] | |
| Multiple myeloma [ICD-11: 2A83; ICD-10: C90.0] | Phase 1/2 | [3] | ||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H34FNO5
|
|||
| Canonical SMILES |
CC(C)C1=C(C(=C(C(=N1)C(C)C)COC)C2=CC=C(C=C2)F)C=CC(CC(CC(=O)O)O)O
|
|||
| InChI |
1S/C26H34FNO5/c1-15(2)25-21(11-10-19(29)12-20(30)13-23(31)32)24(17-6-8-18(27)9-7-17)22(14-33-5)26(28-25)16(3)4/h6-11,15-16,19-20,29-30H,12-14H2,1-5H3,(H,31,32)/b11-10+/t19-,20-/m1/s1
|
|||
| InChIKey |
SEERZIQQUAZTOL-ANMDKAQQSA-N
|
|||
| CAS Number |
CAS 145599-86-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
10167, 822164, 7978896, 10299839, 10852026, 14809054, 14858094, 36888654, 46505877, 46518451, 48415746, 50067077, 50070698, 50728881, 51091965, 56312092, 56313141, 56313595, 92308707, 93166525, 93578306, 103541455, 104635877, 126681828, 134339434, 134339836, 135259857, 135650063, 137002687, 142742086, 160963785, 164788182, 164807583, 176484089, 179116613, 184546299, 198953954, 223659548, 223898596, 226406536, 226406537, 241035409, 252347182
|
|||
| ChEBI ID |
CHEBI:3558
|
|||
| ADReCS Drug ID | BADD_D00415 | |||
| SuperDrug ATC ID |
C10AA06
|
|||
| SuperDrug CAS ID |
cas=145599866
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | HMG-CoA reductase (HMGCR) | Target Info | Inhibitor | [3], [4], [5] |
| BioCyc | Superpathway of geranylgeranyldiphosphate biosynthesis I (via mevalonate) | |||
| Superpathway of cholesterol biosynthesis | ||||
| Mevalonate pathway | ||||
| KEGG Pathway | Terpenoid backbone biosynthesis | |||
| Metabolic pathways | ||||
| Biosynthesis of antibiotics | ||||
| AMPK signaling pathway | ||||
| Bile secretion | ||||
| NetPath Pathway | IL5 Signaling Pathway | |||
| TGF_beta_Receptor Signaling Pathway | ||||
| TSH Signaling Pathway | ||||
| Panther Pathway | Cholesterol biosynthesis | |||
| Pathwhiz Pathway | Steroid Biosynthesis | |||
| WikiPathways | Statin Pathway | |||
| Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | ||||
| Activation of Gene Expression by SREBP (SREBF) | ||||
| SREBF and miR33 in cholesterol and lipid homeostasis | ||||
| Integrated Breast Cancer Pathway | ||||
| SREBP signalling | ||||
| Cholesterol Biosynthesis | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2950). | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001906) | |||
| REF 3 | Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. | |||
| REF 4 | Emerging antidyslipidemic drugs. Expert Opin Emerg Drugs. 2008 Jun;13(2):363-81. | |||
| REF 5 | HMG-CoA reductase inhibitor has protective effects against stroke events in stroke-prone spontaneously hypertensive rats. Stroke. 2003 Jan;34(1):157-63. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.